These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 21724541)

  • 1. Insulin-mediated "pseudoacromegaly".
    Sam AH; Tan T; Meeran K
    Hormones (Athens); 2011; 10(2):156-61. PubMed ID: 21724541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin resistance and pseudoacromegaly: A case report.
    Moradi L; Amiri F; Shahbazian H
    Diabetes Metab Syndr; 2019; 13(2):901-903. PubMed ID: 31336543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pseudoacromegaly-A challenging entity in the endocrine clinic: A systematic review.
    Marques P; Sapinho I; Korbonits M
    Clin Endocrinol (Oxf); 2024 Jun; 100(6):542-557. PubMed ID: 38549284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Body mass index and insulin-like growth factor 1 as risk factors for discordant growth hormone and insulin-like growth factor 1 levels following pituitary surgery in acromegaly.
    Zhang S; Li Y; Guo X; Gao L; Lian W; Yao Y; Feng M; Bao X; Wang R; Xing B
    J Formos Med Assoc; 2018 Jan; 117(1):34-41. PubMed ID: 28341329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Young female with acromegaloid features and pituitary macroadenoma: what is your diagnosis?
    Hernán Martínez J; Figueroa-Núñez C; Mansilla-Letelier P; Palermo-Garofalo C; Santiago M; Torres O; Trinidad R; Mangual-García M; Sánchez A; Gutierrez M; Miranda Mde L; González E
    Bol Asoc Med P R; 2014; 106(1):49-53. PubMed ID: 24791366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Approach to the Patient With Pseudoacromegaly.
    Marques P; Korbonits M
    J Clin Endocrinol Metab; 2022 May; 107(6):1767-1788. PubMed ID: 34792134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low insulin resistance after surgery predicts poor GH suppression one year after complete resection for acromegaly: a retrospective study.
    Edo N; Morita K; Suzuki H; Takeshita A; Miyakawa M; Fukuhara N; Nishioka H; Yamada S; Takeuchi Y
    Endocr J; 2016 May; 63(5):469-77. PubMed ID: 26949262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pseudoacromegaly Associated with Non-Functioning Pituitary Adenoma.
    Alotaibi A; Habib A; Osman M; Alzahrani K; Alzahrani F
    Eur J Case Rep Intern Med; 2020; 7(12):001950. PubMed ID: 33313006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin-mediated pseudoacromegaly: clinical and biochemical characterization of a syndrome of selective insulin resistance.
    Flier JS; Moller DE; Moses AC; O'Rahilly S; Chaiken RL; Grigorescu F; Elahi D; Kahn BB; Weinreb JE; Eastman R
    J Clin Endocrinol Metab; 1993 Jun; 76(6):1533-41. PubMed ID: 8388881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acromegaly presenting with low insulin-like growth factor-1 levels and diabetes: a case report.
    Wijayaratne DR; Arambewela MH; Dalugama C; Wijesundera D; Somasundaram N; Katulanda P
    J Med Case Rep; 2015 Oct; 9():241. PubMed ID: 26514337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormonal diagnosis of GH hypersecretory states.
    Grottoli S; Gasco V; Ragazzoni F; Ghigo E
    J Endocrinol Invest; 2003; 26(10 Suppl):27-35. PubMed ID: 15497657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects.
    Gola M; Doga M; Bonadonna S; Mazziotti G; Vescovi PP; Giustina A
    Pituitary; 2006; 9(3):221-9. PubMed ID: 17036195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin-mediated pseudoacromegaly: a case report and review of the literature.
    Yaqub A; Yaqub N
    W V Med J; 2008; 104(5):12-5. PubMed ID: 18846753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly.
    Bastemir M; Akin F; Yaylali GF
    Neuroendocrinology; 2007; 86(2):119-23. PubMed ID: 17671378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin-like growth factor-I: marker for diagnosis of acromegaly and monitoring the efficacy of treatment.
    Brabant G
    Eur J Endocrinol; 2003 Apr; 148 Suppl 2():S15-20. PubMed ID: 12670296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are there alternative tests for diagnosis of acromegaly?
    Popovic V
    J Endocrinol Invest; 2005; 28(11 Suppl International):73-4. PubMed ID: 16625850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic tests and basal values for defining active acromegaly.
    Tzanela M
    Neuroendocrinology; 2006; 83(3-4):200-4. PubMed ID: 17047383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of long-term remission of acromegaly following surgery.
    Krieger MD; Couldwell WT; Weiss MH
    J Neurosurg; 2003 Apr; 98(4):719-24. PubMed ID: 12691394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of the thyrotropin-releasing hormone test in pre-clinical acromegaly.
    Kageyama K; Moriyama T; Sakihara S; Takayasu S; Nigawara T; Suda T
    Tohoku J Exp Med; 2005 Aug; 206(4):291-7. PubMed ID: 15997199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac and metabolic effects of chronic growth hormone and insulin-like growth factor I excess in young adults with pituitary gigantism.
    Bondanelli M; Bonadonna S; Ambrosio MR; Doga M; Gola M; Onofri A; Zatelli MC; Giustina A; degli Uberti EC
    Metabolism; 2005 Sep; 54(9):1174-80. PubMed ID: 16125529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.